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Abstract 
The small GTP-binding protein ARF has been shown recently to regulate phospholipase D (PLD). In order to investigate the role of ARF proteins 
in regulated exocytosis, we have used the N-terminal peptide ARF1(2-17) of the ARFl protein. ARFl reconstituted PLD activity in cytosol-depleted 
HL60 cells was inhibited by ARF1(2-17). In the presence of endogenous cytosol, ARF1(2-17) also inhibited GTP-y-S-stimulated PLD activity and 
exocytosis. Mastoparan Politses jadwagae and mastoparan Vespula lewisii which exhibit similar structural properties to ARF1(2-17) also inhibited 
GTP-y-S-stimulated PLD and exocytosis. GTP-y-S-stimulated phospholipase C-B (PLC-/?) was also inhibited by ARF(2-17) and mastoparan. In 
cytosol-depleted HL60 cells, the ARF(2-17) inhibited the reconstitution of GTP-y-S-stimulated PLC;B activity with exogenously-added PLC,Bl and 
phosphatidylinositol transfer protein. We conclude that the widely-used ARF1(2-17) peptide inhibits both ARF-independent (i.e. PLC-B) and 
ARF-dependent pathways (i.e. PLD) and therefore cannot be regarded as a specific inhibitor of ARF function. 
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1. Introduction 
Activation of phospholipase D (PLD) by cell-surface 
receptors is a widespread response observed in many cell 
types [l]. Studies in cell-free systems and in permeabil- 
ized cells has indicated that PLD activity is regulated by 
ADP-ribosylation factors, ARFl and ARF3 [2,3]. ADP- 
ribosylation factor (ARF), a small GTP-binding protein, 
was originally identified as the protein co-factor required 
for efficient ADP-ribosylation of the c1 sub-unit of G, by 
cholera toxin [4]. More recently, ARF has been shown 
to be involved in vesicular trafficking between the ER 
and cis-Golgi compartment [5], endosome-endosome fu- 
sion [6] and budding of coated vesicles from the Golgi 
[7]. In yeast two genes encode the ARF proteins - ARFl 
and ARF2. The deletion of both genes is lethal, while the 
deletion of ARFl alone results in the disruption of the 
secretory pathway [S]; this can be rescued by the addition 
of human ARFl or ARF4 proteins [9] indicating the 
highly conserved nature of these proteins. 
In many cell types including HL60 cells and neutro- 
phils, GTP-7-S activates exocytosis as well as PLD activ- 
ity when added to permeabilized cells [lo]. Exocytosis in 
many cell-types is inhibited by alcohols including ethanol 
[IO]. Since alcohols are known to interfere with the pro- 
duction of PA by PLD by diverting it to form phosphat- 
idylalcohols, this suggested that a strong link existed 
between exocytosis and PLD activity [lo]. Since alcohols 
are not very specific in their actions, it was desirable to 
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find an alternative means of inhibiting PLD. The identi- 
fication of ARF as an activator of PLD allowed us to use 
the previously-characterised inhibitory ARF(2-17) pep- 
tide as a possible inhibitor of PLD and exocytosis. 
We report here that ARF1(2-17) inhibits ARFl-re- 
constituted PLD activity in HL60 cells depleted of their 
endogenous cytosol. In addition, the peptide also inhibits 
both exocytosis and PLD activity stimulated by GTP-)I- 
S when added to the cells simultaneously with the perme- 
abilizing agent, streptolysin 0. Since the ARF peptide is 
amphipathic, 2 forms of mastoparan which are also am- 
phipathic were used as controls. Both mastoparans were 
found to inhibit exocytosis and PLD activity similarly to 
ARF1(2-17). To further check the specificity of the pep- 
tides, their effect on G-protein-regulated phospholipase 
Cj? (PLC /I) was also monitored. As well as inhibiting 
PLD activity and exocytosis, inhibition of PLC j? was 
also observed indicating that ARF1(2-17) may not act 
as specifically as previously thought. 
2. Materials and methods 
2.1. Materials 
Culture media (RPM1 1640 and Medium 199) were purchased from 
Flow laboratories. Foetal Calf Serum was from Imperial Laboratories. 
Streptolysin 0 was obtained from Wellcome Diagnostics. Guanosine 
5’-[y-thioltriphosphate (GTP-y-S) and ATP were purchased from 
Boehringer-Mannheim. [methyl-‘HICholine chloride and myo-[2- 
‘Hlinositol were obtained from Amersham. Mastoparan-Polbtes jad- 
wagae (M-8528) and Mastoparan-Vespula ewisii (M-5280) (purity of 
both mastoparans: minimum 97% by HPLC) and all other chemicals 
were from Sigma. ARFl was prepared from bovine brain cytosol as 
described previously [2], PI-TP was purified from bovine brain cytosol 
[ll] and PLC;Bl was purified from bovine brain membranes [12]. 
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ARF(2-I 7) was synthesised on an applied Biosystems 430A using Fmoc 
chemistry. Purity was determined by HPLC, automated amino terminal 
sequencing and by time of flight mass analysis using a FinniganMAT 
Lasermat. 
2.2. Culturing and labelling of HMO cells 
HL60 cells were maintained in culture as previously described 1131. 
Cells were either labelled with [methyl-‘HIcholine chloride for 48-h if 
PLD activity was being monitored [14] or myo-[2-3H]-inositol for 48 h 
for measuring PLC activity [13]. 
2.3. Reconstitution of PLD with ARFl in cytosol-depleted cells 
[methyl-3H]choline-labelled HL60 cells (50 ml, lo6 cells/ml) were cen- 
trifuged at 450 x g for 5 min and then washed twice in 50 ml of 20 mM 
PIPES, 137 mM NaCl and 3 mM KC1 (pH 6.8) (referred to as PIPES 
buffer). Cells were then resuspended in 4.5 ml of PIPES buffer and 
incubated at 37°C for 20 min to equilibriate. The cells were permeabil- 
ized with 0.6 i.u./ml streptolysin 0 at pCa 7 for 30 min so that cytosolic 
proteins would leak out. The nermeabilized cells were washed in PIPES 
buffer and centrifuged at 2,&O x g for 5 min at 4°C. Cells were then 
resuspended in the required amount of PIPES buffer supplemented 
with 2 x concentrated assay cocktail (final concentrations in assay - 
1 mM MgATP, 2 mM MgCl,, Cal’ buffered with 3 mM EGTA (pCa 
5). The cells were then added to tubes containing ARFl, GTP-y-S and 
ARF1(2-17) as indicated in a total assay volume of 50~1. The reaction 
was initiated by transferring the tubes from ice to 37°C and was incu- 
bated for 30 min. The reaction was then quenched with chloroform/ 
methanol (1: 1) and processed for choline release as previously de- 
scribed [14]. 
2.4. Assay for GTP-Y-S-stimulated PLD activity and exocytosis 
Prelabelled HL60 cells (50 ml. lo6 cells/ml) were centrifuaed at 
450 x g for 5 min and then washed twice in 50 kof PIPES buffer. Cells 
were then resuspended in4.5 ml of PIPES buffer and incubated at 37°C 
for 20 min to equilibrate. The cells were then transferred to tubes 
containing assay cocktail (final concentrations in assay - 0.6 i.u/ml 
streptolysin 0; 1 mM MgATP; 2 mM MgCl,; Ca” buffered with 3 mM 
EGTA (pCa 5)) and f peptides and 10 PM GTP-y-S in total volume 
of 100 pl. The samples were incubated for 10 min at 37°C and then 
transferred to ice followed by centrifugation at 2,000 x g for 5 min at 
4°C. 50~1 of the supematant was then removed and assayed for exocy- 
tosis of hexosaminidase as previously described [lo]. The remainder of 
the incubation mixture was quenched and processed for choline release 
P41. 
2.5. Reconstitution of GTP-y-S-stimulated PLCactivity with PI-TP and 
PLC+I in cytosol-depleted cells 
[rmInositol labelled HL60 cells were used; they were handled as for 
the PLD reconstitution assay except that during permeabilization, 
2 mM MgATP was also present and the assay cocktail consisted of 
2 mM MgATP, 2 mM 2,3_diphosphoglycerate, 10mM LiCl, 2 mM 
MgCl, and Ca” buffered with 3 mM EGTA (pCa 6) (final concentra- 
tions). Total assay volume was 55 ~1. The assay was incubated for 20 
min at 37°C. The reaction was quenched with 1 ml of ice-cold 0.9% 
NaCl. The cells were then sedimented at 2,000 x g for 5 min at 4°C and 
the supematant was removed and used for the assay of released inositol 
phosphates [IS]. 
2.6. Assay for GTP-y-S-stimulated PLC activity 
GTP-y-S-stmulated PLC activity was monitored as for PLD activity 
except that the assay cocktail consisted of 0.6 i.u/ml, 2 mM MgATP, 
2 mM MgCl,, 10 mM LiCl, 2 mM 2,3_diphosphoglycerate nd pCa 6, 
final concentrations. After 10 min incubation at 37°C the reaction was 
quenched and assayed for inositol phosphates [IS]. 
2.7. Presentation of results 
All assays were done in duplicate. Each set of experiments were 
performed at least twice under identical conditions and most observa- 
tions were verified on 34 occasions with slight modifications in the 
protocol. The data shown are from representative experiments. 
3. Results 
Streptolysin 0 allows the efBux of cytosolic proteins 
from HL60 cells within 5 min [13]. GTP-y-S-stimulated 
PLD becomes refractory when HL60 cells are permeabil- 
ized first with streptolysin 0 and subsequently triggered 
with GTP-~4. GTP-y-S-stimulated PLD activity can be 
reconstituted with exogenously-added ARFl to the cy- 
tosol-depleted HL60 cells [2]. We examined the effect of 
the N-terminal ARF1(2-17) peptide on this ARFl-re- 
constituted PLD activity. Cytosol-depleted HL60 cells 
were incubated in the presence and absence of ARFl and 
GTP-)I-S with varying concentrations of ARF1(2-17) 
(Fig. 1). As reported previously, ARFl reconstituted 
GTP-y-S-dependent PLD activity but ARFl or GTP-r- 
S alone were insufficient. As the concentration of peptide 
was increased there was a corresponding inhibition of 
ARFl-dependent PLD activity with maximum inhibi- 
tion occurring at 30 ,uM. The small endogenous response 
observed with GTP-7-S alone was also inhibited by 
ARF1(2-17) peptide. 
When GTP-y-S plus Ca*+ (pCa 5) is added to HL60 
cells simultaneously with streptolysin 0, a robust activa- 
tion of PLD is seen [16]. This activation is presumed to 
be utilising endogenous ARF proteins and therefore 
should be susceptible to inhibition by the ARF1(2-17) 
peptide. Fig. 2A illustrates that PLD activation is inhib- 
ited with increasing concentrations of ARF1(2-17). It 
effectively blocked PLD activity with a half maximal 
inhibition at 10 PM and maximal inhibition at 30 PM. 
These values are similar to those reported for its effects 
on intra-golgi transport [7], ER to cis-golgi [5] en- 
dosome-endosome fusion [6] and ARF reconstitution of 
PLD activity (see Fig. 1). 
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Fig. 1. Inhibition of ARFl-reconstituted PLD activity in cytosol-de- 
pleted HL60 cells by the ARF1(2-17) peptide. [‘HIcholine-labelled cells 
were permeabilized for 30 min to deplete the cytosolic proteins. The 
washed cells were incubated with GTP-y-S (10pM) and 625 ng ARFl 
(assay volume, 50 ~1) as indicated for 30 min. [‘HICholine release in the 
supematant was monitored and is expressed as a percentage of radioac- 
tivity incorporated into the choline-labelled lipids. (0), no additions; 
(o), 10 PM GTP-r-S; (v), 625 ng ARFl; (v), 10 PM GTP-r-S + 625 
ng ARFl. 
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Fig. 2. Effect of ARF1(2-17) and mastoparan Politses jadwagae and mastoparan Vespula lewisii on PLD activity and exocytosis stimulated with 
GTP-y-S in HL60 cells. HL60 cells were incubated with streptolysin 0 in the presence of GTP-y-S (10 ,uM) and peptides as indicated. (A) Release 
of [‘HIcholine and (B) exocytosis of hexosaminidase was monitored from the same cell preparation. Open symbols, no GTP-y-S; closed symbols, 
10 ,uM GTP-y-S. (0, l ), ARF1(2-17) (v, v), mastoparan Politses jadwagae; (0, n ) mastoparan Vespula lewisii. 
A correlation between PLD activity and exocytosis 
has previously been observed [lo] and the well docu- 
mented evidence for the role of ARF in vesicular trans- 
port [5-7,171 led us to investigate the effect of ARF1(2- 
17) on exocytosis in HL60 cells. GTP-y-S plus Ca” (pCa 
5) when added with streptolysin 0 stimulates exocytosis 
[13]. The secretory response (measured in the same ex- 
periment as PLD activity) was also inhibited by 
ARF1(2-17) (Fig. 2B); both responses were inhibited 
half-maximally at 10 PM. 
Exocytosis from HL60 cells can be triggered by multi- 
ple effecters. Sub-maximal exocytosis from permeabil- 
ized cells can be triggered by (a) Ca” alone (pCa 5) 
which requires MgATP (b) GTP-7-S alone (pCa 7) which 
requires MgATP (c) Ca2+ plus GTP-y-S (which does not 
require MgATP). Maximal exocytosis is observed with 
Ca2’ plus GTP-y-S in the presence of MgATP (Table 1 
and [lo]). All these different components of MgATP- 
dependent and independent exocytosis are inhibited by 
the presence of 30 PM ARF1(2-17) peptide (Table 1). 
ARF1(2-17) is an amphipathic peptide and has been 
shown to adopt an a-helical structure in hydrophobic 
environments [7]. It appears that it may be the conforma- 
tion of the peptide that is more important rather than its 
specific amino acid sequence as it has been shown that 
the N-terminal 16 residues from both hARF1 and 
hARF4 inhibit ER to Golgi transport. These two pep- 
tides only share 50% sequence homology but both adopt 
a-helical conformations [5]. Another amphipathic pep- 
tide of similar size (viz 14 amino acids) which also forms 
an a-helix is mastoparan [l&19]. We therefore used two 
mastoparan peptides as a control to establish the speci- 
ficity of ARF1(2-17) peptide. Two forms of mastoparan 
were used - Mastoparan Vespula lewisii (referred to as 
mastoparan V.) and mastoparan Polistes jadwagae (re- 
ferred to as mastoparan P.). A comparison of the amino 
acid composition of mastoparans with the ARF1(2-17) 
is shown in Table 2. 
Like ARF1(2-17), both mastoparans inhibited GTP- 
y-S-stimulated PLD activity (Fig. 2A) and exocytosis 
(Fig. 2B). Although the secretory response was inhibited 
by all the 3 peptides, mastoparan P. was not quite as 
effective as the others at inhibiting GTP-y-S-stimulated 
exocytosis (Fig. 2B). This was not investigated further. 
To analyse the specificity of the ARF1(2-17) peptide, 
we examined the effect of ARF(2-17) and mastoparan 
V. on GTP-y-S-stimulated PLC activity. This pathway 
is well-defined; G-proteins of the G, family and By-sub- 
units derived from pertussis toxin-sensitive G-proteins 
are responsible for activating PLC-jI isoforms [2&22]. In 
Table 1 
Inhibition of exocytosis by ARF(2-17) 
% Exocytosis 
-MgATP +MgATP 
Control +ARF(2-17) Control +ARF(2-17) 
pCa 7 5 5 6 s 
pCa 7 + GTP-y-S 6 5 16 8 
pCa 5 
pCa 5 + GTP-y-S 2: 
5 12 8 
6 50 11 
HL60 cells were permeabilized with streptolysin 0 in the presence of 
Ca2’ buffers, GTP-y-S (10 PM), MgATP (1 mM) and ARF (2-17) 
peptide (30 PM) as indicated. After 10 min at 37°C the cells were 
transferred to ice and centrifuged. The supernatant was analysed for 
the release of hexosaminidase. 
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Fig. 3. (A) ARF1(2-17) and (B) Mastoparan Vespula Iewisii inhibit GTP-y-S-stimulated phospholipase Cb activity in HL60 cells. [3H]inositol-labelled 
cells were incubated with streptolysin 0 in the presence of GTP-r-S (10 PM) and peptides as indicated for 10 min. [‘Hlinositol phosphates released 
in the supematant were monitored and are expressed as a percentage of radioactivity incorporated into the inositol-labelled lipids. (0), no GTP-y-S; 
(o), 10 iM GTP-y-S. 
addition, a cytosolic protein, phosphatidylinositol trans- 
fer protein (PI-TP) is also required [l 11. There is no 
known requirement for ARF proteins in this signalling 
pathway. Addition of GTP-y-S in the presence of strep- 
tolysin 0 stimulates PLC /3 activity [13] and this is inhib- 
ited by ARF1(2-17) (Fig. 3A) and by mastoparan V. 
(Fig. 3B). Both peptides inhibited GTP-y-S-stimulated 
PLC p activity with maximum inhibition occurring at 10 
,uM; this is lower than the concentrations required for 
maximum inhibition of exocytosis and PLD activity. 
GTP-y-S-stimulated PLC activity is refractory in cy- 
tosol-depleted HL60 cells and can be reconstituted by the 
addition of PI-TP [l l] or PLC-Bl [15]. GTP-y-S-stimu- 
lated PLC B activity was reconstituted in cytosol-de- 
pleted cells with PI-TP or PLCgl added alone or added 
together. ARF1(2-17) (30 ,uM) effectively abolished the 
reconstitution under all conditions (Fig. 4). 
4. Discussion 
N-terminal ARF peptides have been extensively used 
as specific inhibitors of ARF function to elucidate the 
role(s) of ARF in vesicular trafficking [5-71 and regu- 
lated exocytosis [17]. In this study we have used the 
N-terminal 16 residues of ARF 1 (ARF 1(2-l 7)) to inves- 
tigate the role of ARF in both the PLD and exocytotic 
pathways in HL60 cells. 
The reconstitution of GTP-y-S-mediated PLD activity 
has been shown to be dependent on the presence of ARF 
proteins [2,3], therefore it was not surprising that 
ARF1(2-17) inhibited ARFl-reconstituted PLD activity 
(Fig. 1). The inhibition of both PLD activity and exocy- 
tosis in permeabilized cells by ARF1(2-17) (Fig. 2) indi- 
cated that ARF-regulated PLD may be directly involved 
in exocytosis in these cells. 
It is thought that the conformation ARF1(2-17) 
adopts is important for inhibition of ARF function. 
ARFl(2-17) forms an cc-helix in a hydrophobic environ- 
ment [7]. The amino acid composition is important in 
that the equally spaced hydrophobic residues (Ileu-Phe- 
X-X-Leu-Phe-X-X-Leu-Phe) result in the formation of 
the a-helix with all the charged residues aligned on the 
same face of the helix [7]. Mastoparan peptides isolated 
from wasp venom are also amphipathic and form an 
a-helix with the charged residues aligned on one face 
[l&23] as does ARF1(2-17). Two forms of mastoparan 
were used, mastoparan V. and mastoparan P. By com- 
parison of the peptide sequences in Table 2 it can be seen 
that mastoparan V. has regularly spaced hydrophobic 
residues (Leu-X-X-Leu-X-X-Leu) like ARF1(2-17). The 
hydrophobic residues in mastoparan P. are not so regu- 
larly spaced. Mastoparan V. therefore is likely to adopt 
an a-helical conformation that is very similar to 
ARF1(2-17), whereas that adopted by mastoparan P. 
may not be quite so similar. 
When these peptides were introduced into permeabil- 
ized cells, they inhibited the GTP-y-S-stimulated PLD 
activity (Fig. 2A) and exocytosis (Fig. 2B). It was noted 
that mastoparan P. was not as effective at inhibiting 
Table 2 
Comparison of the peptide sequences used in this study 
ARFl (2-17) GNIFANLFKGLFGKKE 
Mastoparan V. IN=ELAzIL 
Mastoparan P VDZKIGQHILSV --- -- 
Letters that are in bold and underlined indicate hydrophobic residues. 
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m PLC,91 +GTP[S] 
m PI-TP+GTP[S] 
m PLC@l+PI-TP 
+CTP[S] 
O- 
Control ARF(2- 17) 
Fig. 4. ARF1(2-17) inhibits reconstituted G-protein-stimulated phos- 
pholipase C/3 activity in cytosol-depleted HL60 cells. [‘H]Inositol-la- 
belled cells were permeabilized for 30 min to deplete the cytosolic 
proteins. The washed cells were incubated with GTP-y-S (10 PM), 
ARF(2-17) (30 PM final), PI-TP (675 ng) and PLC-/Jl (375 ng) as 
indicated in an assay volume of 55 ~1 for 20 min. [-‘H]Inositol phos- 
phates released in the supernatant were monitored and are expressed 
as a percentage of radioactivity incorporated into the inositol-labelled 
lipids. 
exocytosis as PLD (Fig. 2). The observation that 
ARF1(2-17) and mastoparans were both inhibitory for 
PLD activity and exocytosis uggests that the conforma- 
tion adopted by these peptides is more important than 
their amino acid composition. 
Mastoparan has been shown to promote nucleotide 
exchange by G-proteins [19,24], and to stimulate ara- 
chidonic acid release and DNA synthesis in quiescent 
Swiss 3T3 cells, although it was cytotoxic at higher con- 
centrations (30 PM) [25]. It has also been shown to stim- 
ulate PLC activity in intact differentiated HL60 cells but 
to inhibit the same response in streptolysin O-permeabil- 
ized cells [26]. Mastoparan has also been shown to dis- 
rupt membranes by increasing their permeability [27,28]. 
Although ARF1(2-17) has not been examined so exten- 
sively, it is very likely that, like the mastoparans, 
ARF1(2-17) may equally affect many biologically unre- 
lated responses. 
To further emphasize the non-specificity of ARF1(2- 
17), we examined its effects on GTP-y-S-stimulated PLC 
activity. This activity was reconstituted with purified 
proteins (PI-TP and PLC-/?l) in the cytosol-depleted 
HL60 cells under conditions where the majority of ARF 
proteins have leaked out. Inhibition of this reconstituted 
PLC-p activity was also inhibited by ARF1(2-17) (Fig. 
4). Addition of ARFl does not reconstitute GTP-Y-S- 
stimulated PLC /.I activity (data not shown). There is no 
evidence for ARF requirement in the G-protein-stimu- 
lated PLC-p pathway, i.e. it is an ARF-independent 
pathway. Inhibition by ARF1(2-17) of this pathway seri- 
ously questions the use of these peptides as a means of 
inhibiting ARF function. In conclusion, the data pre- 
sented in this paper indicate that results obtained using 
ARF1(2-17) should be interpreted with caution due to 
its lack of specificity. 
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